119 related articles for article (PubMed ID: 8808233)
1. Calcium acetate versus calcium carbonate and erythropoietin dosages in haemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Nephrol Dial Transplant; 1995 Dec; 10(12):2321-4. PubMed ID: 8808233
[No Abstract] [Full Text] [Related]
2. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia.
Rao DS; Shih MS; Mohini R
N Engl J Med; 1993 Jan; 328(3):171-5. PubMed ID: 8417383
[TBL] [Abstract][Full Text] [Related]
3. [MIBI and parathyroid gland function in secondary hyperparathyroidism].
Martín F; Sarró F; Verdú J; González A; Martínez F
Nefrologia; 2004; 24(4):344-50. PubMed ID: 15455494
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. Suppression of secondary hyperparathyroidism in uraemia: acute and chronic studies.
Muirhead N; Catto GR; Edward N; Adami S; Manning RM; O'Riordan JL
Br Med J (Clin Res Ed); 1984 Jan; 288(6412):177-9. PubMed ID: 6419845
[TBL] [Abstract][Full Text] [Related]
6. Effect of one haemodialysis treatment on the plasma concentrations of intact parathyroid hormone and ionised calcium: usefulness of end-dialysis values in evaluating the suppressibility of hyperparathyroidism.
Pietilä K; Mustonen J; Mörsky P; Seppälä E; Pasternack A; Koivula T
Nephrol Dial Transplant; 1989; 4(2):115-8. PubMed ID: 2496352
[TBL] [Abstract][Full Text] [Related]
7. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis.
Pflanz S; Henderson IS; McElduff N; Jones MC
Nephrol Dial Transplant; 1994; 9(8):1121-4. PubMed ID: 7800211
[TBL] [Abstract][Full Text] [Related]
8. Control of parathyroid function in patients with a short history of hemodialysis.
Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
[TBL] [Abstract][Full Text] [Related]
9. The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study.
Schaefer K; Scheer J; Asmus G; Umlauf E; Hagemann J; von Herrath D
Nephrol Dial Transplant; 1991; 6(3):170-5. PubMed ID: 1866045
[TBL] [Abstract][Full Text] [Related]
10. Reduction by cimetidine of serum parathyroid hormone levels in uremic patients.
Jacob AI; Lanier D; Canterbury J; Bourgoignie JJ
N Engl J Med; 1980 Mar; 302(12):671-4. PubMed ID: 7354765
[No Abstract] [Full Text] [Related]
11. High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients.
Sawyer N; Noonan K; Altmann P; Marsh F; Cunningham J
Nephrol Dial Transplant; 1989; 4(2):105-9. PubMed ID: 2496350
[TBL] [Abstract][Full Text] [Related]
12. Calcium mass balance and behavior of intact immunoreactive parathyroid hormone in acetate-free biofiltration: acute and one-year evaluation.
de Vincenzi A; Bellazzi R; Santagostino M; Romanini D; Nai M; Gazo A; Bacchella L; Gini A
Blood Purif; 1994; 12(2):85-94. PubMed ID: 7826579
[TBL] [Abstract][Full Text] [Related]
13. Impact of recombinant erythropoietin on sexual function in hemodialysis patients.
Schaefer RM; Kokot F; Heidland A
Contrib Nephrol; 1989; 76():273-81; discussion 281-2. PubMed ID: 2684527
[No Abstract] [Full Text] [Related]
14. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
15. Medical management of secondary hyperparathyroidism in uremia.
Drüeke TB
Am J Med Sci; 1999 Jun; 317(6):383-9. PubMed ID: 10372838
[TBL] [Abstract][Full Text] [Related]
16. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
[TBL] [Abstract][Full Text] [Related]
17. Reversal of hyperparathyroidism in severe uremics following very low-protein and low-phosphorus diet.
Barsotti G; Morelli E; Guiducci A; Ciardella F; Giannoni A; Lupetti S; Giovannetti S
Nephron; 1982; 30(4):310-3. PubMed ID: 7110461
[No Abstract] [Full Text] [Related]
18. Anemia and secondary hyperparathyroidism in chronically hemodialyzed patients.
Rathaus M; Bernheim J
Isr J Med Sci; 1979 May; 15(5):415-7. PubMed ID: 447508
[TBL] [Abstract][Full Text] [Related]
19. [Autologous epithelial body transplantation in the surgical treatment of secondary azotemic hyperparathyroidism].
Frei U; Klempa I; Fassbinder W; Koch KM
Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1315-9. PubMed ID: 611843
[No Abstract] [Full Text] [Related]
20. Successful control of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis using magnesium carbonate and calcium carbonate as phosphate binders.
Parsons V; Baldwin D; Moniz C; Marsden J; Ball E; Rifkin I
Nephron; 1993; 63(4):379-83. PubMed ID: 8459870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
